A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

Exclusion Criteria

• •For participants with Type 2 Diabetes (T2D):
• •* Have Type 1 Diabetes (T1D), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2D.
• •* Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within the 180 days prior to screening.
• •Have renal impairment measured as estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m², calculated by Japanese Society of Nephrology coefficient-modified chronic kidney disease-epidemiology equation during screening.
• •Have a known clinically significant gastric emptying abnormality.
• •For participants without Type 2 diabetes (T2D): Have any type of diabetes with hemoglobin A1c (HbA1c) ≥6.5 %.
• •Have a self-reported change in body weight \>5 kg (11 pounds) within 90 days prior to screening.
• •Have chronic kidney disease.
• •Have lupus or rheumatoid arthritis.
• •Have the following cardiovascular conditions within 90 days prior to screening.
• •Have acute or chronic hepatitis.